PMA supplement
P880027 S062: PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA)
FDA PMA supplement · 30-Day Notice · Boston Scientific
Key facts
| Original PMA | P880027 |
|---|---|
| Supplement number | S062 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) |
| Generic name | Catheters, transluminal coronary angioplasty, percutaneous |
| Applicant | Boston Scientific |
| Product code | LOX |
| Received date | May 29, 2002 |
| Decision date | Jun 25, 2002 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: